37 related articles for article (PubMed ID: 38731811)
1. Synthesis, In Silico and Kinetics Evaluation of
Homolya L; Mathomes RT; Varga L; Docsa T; Juhász L; Hayes JM; Somsák L
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731811
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary docking, kinetics and X-ray crystallography studies of baicalein acting as a glycogen phosphorylase inhibitor and determination of its' potential against glioblastoma in cellular models.
Mathomes RT; Koulas SM; Tsialtas I; Stravodimos G; Welsby PJ; Psarra AG; Stasik I; Leonidas DD; Hayes JM
Chem Biol Interact; 2023 Sep; 382():110568. PubMed ID: 37277066
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of 3-(β-d-Glucopyranosyl)-4-amino/4-guanidino Pyrazole Derivatives and Analysis of Their Glycogen Phosphorylase Inhibitory Potential.
Kun S; Mathomes RT; Docsa T; Somsák L; Hayes JM
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049768
[TBL] [Abstract][Full Text] [Related]
4. Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation.
Zois CE; Hendriks AM; Haider S; Pires E; Bridges E; Kalamida D; Voukantsis D; Lagerholm BC; Fehrmann RSN; den Dunnen WFA; Tarasov AI; Baba O; Morris J; Buffa FM; McCullagh JSO; Jalving M; Harris AL
Cell Death Dis; 2022 Jun; 13(6):573. PubMed ID: 35764612
[TBL] [Abstract][Full Text] [Related]
5. Dual-Target Compounds against Type 2
Sipos Á; Szennyes E; Hajnal NÉ; Kun S; Szabó KE; Uray K; Somsák L; Docsa T; Bokor É
Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33920838
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends.
Khan MAB; Hashim MJ; King JK; Govender RD; Mustafa H; Al Kaabi J
J Epidemiol Glob Health; 2020 Mar; 10(1):107-111. PubMed ID: 32175717
[TBL] [Abstract][Full Text] [Related]
7. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
Goyard D; Kónya B; Czifrák K; Larini P; Demontrond F; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Docsa T; Gergely P; Somsák L; Praly JP; Azay-Milhau J; Vidal S
Org Biomol Chem; 2020 Feb; 18(5):931-940. PubMed ID: 31922157
[TBL] [Abstract][Full Text] [Related]
8. Identification of
Barr D; Szennyes E; Bokor É; Al-Oanzi ZH; Moffatt C; Kun S; Docsa T; Sipos Á; Davies MP; Mathomes RT; Snape TJ; Agius L; Somsák L; Hayes JM
ACS Chem Biol; 2019 Jul; 14(7):1460-1470. PubMed ID: 31243960
[TBL] [Abstract][Full Text] [Related]
9. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
Kun S; Begum J; Kyriakis E; Stamati ECV; Barkas TA; Szennyes E; Bokor É; Szabó KE; Stravodimos GA; Sipos Á; Docsa T; Gergely P; Moffatt C; Patraskaki MS; Kokolaki MC; Gkerdi A; Skamnaki VT; Leonidas DD; Somsák L; Hayes JM
Eur J Med Chem; 2018 Mar; 147():266-278. PubMed ID: 29453094
[TBL] [Abstract][Full Text] [Related]
10. Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase.
Kantsadi AL; Bokor É; Kun S; Stravodimos GA; Chatzileontiadou DSM; Leonidas DD; Juhász-Tóth É; Szakács A; Batta G; Docsa T; Gergely P; Somsák L
Eur J Med Chem; 2016 Nov; 123():737-745. PubMed ID: 27522507
[TBL] [Abstract][Full Text] [Related]
11. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy.
Zois CE; Harris AL
J Mol Med (Berl); 2016 Feb; 94(2):137-54. PubMed ID: 26882899
[TBL] [Abstract][Full Text] [Related]
12. 4(5)-Aryl-2-C-glucopyranosyl-imidazoles as New Nanomolar Glucose Analogue Inhibitors of Glycogen Phosphorylase.
Bokor É; Kun S; Docsa T; Gergely P; Somsák L
ACS Med Chem Lett; 2015 Dec; 6(12):1215-9. PubMed ID: 26713107
[TBL] [Abstract][Full Text] [Related]
13. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
[TBL] [Abstract][Full Text] [Related]
14. Self-Consistent Reaction Field Model for Aqueous and Nonaqueous Solutions Based on Accurate Polarized Partial Charges.
Marenich AV; Olson RM; Kelly CP; Cramer CJ; Truhlar DG
J Chem Theory Comput; 2007 Nov; 3(6):2011-33. PubMed ID: 26636198
[TBL] [Abstract][Full Text] [Related]
15. Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values.
Søndergaard CR; Olsson MH; Rostkowski M; Jensen JH
J Chem Theory Comput; 2011 Jul; 7(7):2284-95. PubMed ID: 26606496
[TBL] [Abstract][Full Text] [Related]
16. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins.
Harder E; Damm W; Maple J; Wu C; Reboul M; Xiang JY; Wang L; Lupyan D; Dahlgren MK; Knight JL; Kaus JW; Cerutti DS; Krilov G; Jorgensen WL; Abel R; Friesner RA
J Chem Theory Comput; 2016 Jan; 12(1):281-96. PubMed ID: 26584231
[TBL] [Abstract][Full Text] [Related]
17. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.
Wu Y; Ding Y; Tanaka Y; Zhang W
Int J Med Sci; 2014; 11(11):1185-200. PubMed ID: 25249787
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, enzyme kinetics and computational evaluation of N-(β-D-glucopyranosyl) oxadiazolecarboxamides as glycogen phosphorylase inhibitors.
Polyák M; Varga G; Szilágyi B; Juhász L; Docsa T; Gergely P; Begum J; Hayes JM; Somsák L
Bioorg Med Chem; 2013 Sep; 21(18):5738-47. PubMed ID: 23938052
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
